Tuesday 5 November 2024

The Pharma Letter Podcast — Episode 8 — Why hasn't the world embraced Sputnik V?

Biotechnology
Simon Wentworth
14 December 2021
kirill_dmitriev_rdif_podcast

More on this story...

Pharmaceutical
Russia's Sputnik Light coronavirus vaccine approved in India
7 February 2022
Pharmaceutical
RDIF announces interim results of 1,000 participant Argentinian study into Sputnik Light
15 October 2021
Pharmaceutical
RDIF and Serum Institute agree manufacturing deal for Sputnik V
13 July 2021
Pharmaceutical
RDIF and UNICEF sign Sputnik V vaccine supply deal
27 May 2021


Companies featured in this story

More ones to watch >


Today's issue

AstraZeneca sees progress in obesity drug trials, highlights new oral option
Pharmaceutical
AstraZeneca sees progress in obesity drug trials, highlights new oral option
5 November 2024
Biotechnology
Nektar sells its PEGylation reagent manufacturing business
5 November 2024
Pharmaceutical
PharmaMar gets $10 million milestone from Janssen for Yondelis
5 November 2024
Pharmaceutical
Photocure’s Hexvix wins Chinese approval
5 November 2024
Pharmaceutical
Vertex ups guidance again as results exceed estimates
5 November 2024
Biotechnology
Transgene and ProBioGen join forces on cancer vaccines
5 November 2024
Biotechnology
Nxera Pharma and Antiverse partner on GPCRs
5 November 2024

Company Spotlight

A Denmark-headquartered company that currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus.




More Features in Biotechnology

Nektar sells its PEGylation reagent manufacturing business
5 November 2024
Transgene and ProBioGen join forces on cancer vaccines
5 November 2024
Nxera Pharma and Antiverse partner on GPCRs
5 November 2024
Frits van Alphen gets Memo CDO job
4 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze